Arcellx (ACLX) Competitors

Genmab A/S (NASDAQ:GMAB) and Arcellx (NASDAQ:ACLX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Do analysts rate GMAB or ACLX?

Genmab A/S presently has a consensus target price of $37.60, suggesting a potential upside of 81.29%. Arcellx has a consensus target price of $111.23, suggesting a potential upside of 71.94%. Given Genmab A/S's higher possible upside, research analysts clearly believe Genmab A/S is more favorable than Arcellx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Arcellx	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07

Which has more volatility & risk, GMAB or ACLX?

Genmab A/S has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, Arcellx has a beta of 0.28, indicating that its stock price is 72% less volatile than the S&P 500.

Is GMAB or ACLX more profitable?

Genmab A/S has a net margin of 35.11% compared to Arcellx's net margin of -211.46%. Genmab A/S's return on equity of 18.08% beat Arcellx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	35.11%	18.08%	14.52%
Arcellx	-211.46%	-35.27%	-22.73%

Which has stronger valuation & earnings, GMAB or ACLX?

Genmab A/S has higher revenue and earnings than Arcellx. Arcellx is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	4.26	$1.14B	$1.76	11.78
Arcellx	$107.94M	33.03	-$107.35M	-$2.99	-21.64

Does the media prefer GMAB or ACLX?

In the previous week, Genmab A/S had 2 more articles in the media than Arcellx. MarketBeat recorded 5 mentions for Genmab A/S and 3 mentions for Arcellx. Arcellx's average media sentiment score of 1.13 beat Genmab A/S's score of 0.88 indicating that Arcellx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcellx	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals hold more shares of GMAB or ACLX?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 96.0% of Arcellx shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 8.4% of Arcellx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Genmab A/S beats Arcellx on 10 of the 16 factors compared between the two stocks.